Navigation Links
Drug Refused to Asbestos-Linked Cancer Patients

A body that is responsible for approving NHS treatments has been accused of placing money before patients//, after it blocked the usage of an anti-cancer drug.

The group analyzed the cost effectiveness of the drug, used to treat the cancer mesothelioma, and concluded that the drug would not be recommended for use except as part of ongoing or new.trial.

Mesothelioma is a kind of cancer that affects the lung lining and nine out of ten cases are due to exposure to asbestos. People who are involved in shipbuilding, railway engineering and asbestos product manufacturing are at an increased risk. . A cure for the disease is not available and pemetrexed disodium treatment is used to maintain the quality of life.

The makers of the drug, Eli Lilly, said it will appeal against the decision. Medical director of Lilly UK, Dr Joanna Nakielny, said: "This is a major blow for patients with mesothelioma, many of whom were unwittingly exposed to asbestos in their working lives making submarines, ships, boilers and trains”.

"This treatment does not save lives, but it can prolong the lives of patients and also improve the quality of the time they have left. Lilly will be formally appealing NICE’s decision." She added.


'"/>




Page: 1

Related medicine news :

1. Smoker Refused Treatment
2. Boy Refused Compensation For HIV Infection Following Hospital Admission
3. One in Ten NHS Dentists Refused To Sign the New Contract
4. Gardasil Refused Subsidy
5. NRI Fights for HIV Child Who was Refused Treatment
6. Fibroids unlikely to Turn Cancerous
7. Virus Level could Predict Cervical Cancer Risk
8. Cancer Doctors Okays Controversial Prostate Therapy
9. Potential New Cancer Gene Identified
10. Consensus on "Combination Therapy" for Breast Cancer
11. Cancers of Colon & Rectum linked to Cigarette Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug Refused Asbestos Linked Cancer Patients

(Date:7/26/2014)... The North America Cyber Security report defines and ... with analysis and forecast of revenue. This market is ... to $33.24 billion by 2019, at a CAGR of ... TOC of the North America Cyber Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:7/26/2014)... SATURDAY, July 26, 2014 (HealthDay News) -- Pools can ... can make themselves sick if they swallow too much ... excitement, it,s common for little ones to get water ... drink from a pool, despite warnings from their parents. ... is harmless, it,s important for parents to realize that ...
(Date:7/26/2014)... July 26, 2014 According ... updated by Vkool.com, this is a comprehensive ... methods for treating all types of ...     Tinnitus due to Ménière's disease ...     Nerve pathway tinnitus ,     Inner, ...
(Date:7/26/2014)... 2014 The U.S. Food & Drug Administration ... a new medication guide for AndroGel to include blood clots ... taking the topical low testosterone medication, notes Wright & Schulte ... makers of the low testosterone theapy drug, has also updated ... or redness as signs of a blood clot in the ...
(Date:7/26/2014)... According to the "Get Rid Tattoo ... a comprehensive guide that provides readers with safe and ... book also teaches them how to fade dark colored ... their own home for drastic results. , Vkool ... book includes step-by-step tutorials and product recommendations for treating ...
Breaking Medicine News(10 mins):Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Don't Let Kids Drink Pool Water 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3
... effect , MONDAY, Oct. 5 (HealthDay News) -- Although ... this isn,t reason enough for most people to stop eating ... blood pressure due to methylmercury will never outweigh the benefits ... in the department of social and preventive medicine at Laval ...
... desired antibodies in some, but effects were fleeting, scientists say ... help cocaine addicts beat their habit is showing some effect ... more than one-third of participants in a new study developed ... this group, cocaine use did go down. But the effects ...
... New Delhi, Singapore and Washington DC (October 5, 2009) SAGE ... by Dr. Prem Reddy, founder and previous Editor-in-Chief of the ... field of cancer research is entering a new and exciting ... modern genetics are beginning to provide new clues into how ...
... Fewer secondary schools in the United States are selling ... according to a survey from the Centers for Disease Control ... in states that have adopted strong school nutrition standards and ... , The report, "Availability of Less Nutritious Snack Foods ...
... Mass., Oct. 5 Hologic, Inc. (Hologic or the ... and supplier of premium diagnostics, medical imaging systems and ... women, today announced plans to release its fourth quarter ... 2009 after market close. In conjunction with the release, ...
... Fred Hutchinson Cancer Research Center have been awarded 60 ... Recovery & Reinvestment Act of 2009. The totals reflect ... the National Institutes of Health. , The individual projects ... benefit every level of researcher at the Hutchinson Center, ...
Cached Medicine News:Health News:Mercury in Fish Linked to High Blood Pressure 2Health News:Mercury in Fish Linked to High Blood Pressure 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:SAGE launches Genes & Cancer 2Health News:Fewer U.S. Schools Selling Less Nutritious Food and Beverages 2Health News:Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday, November 9, 2009 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 3Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 4
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
... VICTOR2 V ... fluorescence polarization, luminescence, ... and absorbance. A ... LANCE assay. All ...
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... readers available today operate with either one, ... speed) or use an imaging process to ... sensitivity and the individual signals can overlap). ... miniature lens array containing 96 parallel micro-objectives. ...
Medicine Products: